# GLOW Legal Status, FDA 503A Category, and Compounding Access | GLOW peptide

> GLOW legal status for the GLOW peptide blend: the constituents sit in FDA's 503A Category 2 today. Access is under active FDA review and may expand in 2026, anchored on a scheduled July 23-24 2026 PCAC meeting.

The momentum is real and the boundary is real. Access to GLOW's constituent peptides is under active FDA review and may expand in 2026 — but as of today they sit in 503A Category 2, and nothing here states a reclassification as done.

## The headline: under active review, restricted today

GLOW legal status is best read as a moving file with a firm present tense. The momentum is genuine: the FDA is actively re-examining this class of peptides, and an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss several of these peptides as candidates for the 503A bulks list [13]. That is a scheduled evaluation, and compounded access to GLOW's constituents may expand in 2026 as that review proceeds.

The present-tense fact is just as real. As of today, the injectable peptides in the GLOW blend sit in FDA's 503A 'Category 2' — bulk substances FDA has identified as potentially presenting significant safety risks — which restricts compounding-pharmacy access [11][12]. Nothing on this page states any reclassification as already done, dated, or certain. This is general information about the regulatory landscape, not medical or legal advice.

## What Category 2 means under sections 503A and 503B

U.S. drug compounding runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered 'outsourcing facilities' that may compound larger batches under cGMP-style oversight [11].

A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Substances not yet listed are evaluated by FDA through a public nomination process with input from PCAC. Under FDA's interim policy, Category 2 substances were nominated with enough information to evaluate but were identified as raising significant safety risks; they are not covered by the enforcement-discretion policy that applies to Category 1, and FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance [11][12]. Being discussed by PCAC is a step in evaluation, not a final listing decision.

## Where each GLOW constituent stands today

The three legs of the blend do not share one status, and the strictest applies to the injected combination.

BPC-157 was placed in Category 2 for 503A compounding, effective with FDA's September 29, 2023 update to the nominated-substances list, citing concerns including potential immunogenicity for certain routes and complexities with peptide impurities and characterization [11]. It is not an FDA-approved drug. BPC-157 is on the published agenda of the July 23-24, 2026 PCAC meeting as a substance 'being considered for inclusion on the 503A Bulks List' — a scheduled discussion, not a decision [13].

TB-500 carries the same posture. FDA placed 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500' in Category 2, effective with the same September 29, 2023 update, citing immunogenicity concerns for certain routes and a lack of important safety information [11]. TB-500 also appears on the July 23-24, 2026 PCAC agenda as a candidate under consideration [13].

GHK-Cu requires two contexts kept separate. As a cosmetic ingredient, GHK-Cu labeled 'Copper Tripeptide-1' is used in topical skincare and is regulated under cosmetics rules, which do not require FDA pre-market approval of the ingredient [14]. As an injectable drug, FDA identified 'GHK-Cu (for injectable routes of administration)' as a bulk substance that may present significant safety risks and placed it in Category 2 for 503A compounding, effective with the September 29, 2023 update [11]. Importantly, GHK-Cu is not on the July 23-24, 2026 PCAC agenda; its injectable form remains in Category 2, separate from the cosmetic Copper Tripeptide-1 context [11][13].

## How legally compounded peptide access works

When a compounded medication is obtained lawfully in the U.S., it follows one pathway. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or for office and batch use, sourced from an FDA-registered 503B outsourcing facility [11].

Telehealth is one channel for the prescriber-evaluation step, not a separate legal status: it is a route to a licensed-prescriber consultation and prescription, and it does not change which substances are eligible to be compounded or remove the need for a legitimate clinical evaluation and a valid prescription.

The ingredient-eligibility caveat is the one that governs this blend. A compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules. Ingredients FDA has flagged for significant safety risks — which currently includes the injectable forms of GLOW's constituents — are not eligible for routine 503A compounding while that status stands. This page names no specific pharmacy, clinic, telehealth provider, or vendor, and offers no dosing, administration, or workaround guidance.

## Access and regulatory questions

### Is GLOW legal?
GLOW is not an FDA-approved drug. Its injectable constituents — BPC-157, TB-500, and injectable GHK-Cu — are in FDA's 503A Category 2 today, which restricts compounding-pharmacy access [11][12]. Topical Copper Tripeptide-1 (GHK-Cu) is a legal cosmetic ingredient in skincare, a separate context [14]. Access to the injectable peptides is under active FDA review and may expand in 2026, but no reclassification has been finalized.

### Can you get GHK-Cu from a compounding pharmacy?
For the injectable drug form, not routinely today: FDA placed 'GHK-Cu (for injectable routes of administration)' in 503A Category 2 effective with its September 29, 2023 update, so it is not within FDA's enforcement-discretion policy for 503A compounding [11]. Topical Copper Tripeptide-1 in cosmetics is a different, legal context [14]. GHK-Cu is not on the July 23-24, 2026 PCAC agenda [13].

### What is the FDA 503A status of GLOW?
GLOW is a non-standardized combination, and the strictest constituent status applies. BPC-157, TB-500, and injectable GHK-Cu are each in 503A Category 2 (effective with FDA's September 29, 2023 update), meaning FDA identified significant safety risks and they fall outside its enforcement-discretion policy [11][12]. BPC-157 and TB-500 are on the July 23-24, 2026 PCAC agenda as candidates under evaluation — a scheduled discussion, not a listing decision [13].

---

Three constituent channels read on one console — GHK-Cu, BPC-157 and TB-500 logged to their studies and their 503A status, with every blend-level gap printed in plain sight, nothing dispensed and nothing for sale.